Yvan Verlinden
Overview
Explore the profile of Yvan Verlinden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lauren A, Braun M, Cazzin C, Colleti K, Cox C, Dietz L, et al.
Bioanalysis
. 2022 Sep;
14(16):1085-1093.
PMID: 36125042
In this manuscript, the European Bioanalysis Forum reports back on their discussions on practical and scientific considerations related to bioanalytical applications of quantitative polymerase chain reaction. This publication follows an...
2.
Van Vooren S, Grayson J, Van Ranst M, Dequeker E, Laenen L, Janssen R, et al.
Life (Basel)
. 2022 Feb;
12(2).
PMID: 35207446
We present our approach to rapidly establishing a standardized, multi-site, nation-wide COVID-19 screening program in Belgium. Under auspices of a federal government Task Force responsible for upscaling the country's testing...
3.
Lauren A, Braun M, Byrne P, Cazzin C, Colletti K, Cox C, et al.
Bioanalysis
. 2021 Oct;
13(23):1723-1729.
PMID: 34708666
Polymerase chain reaction (PCR) is widely used in various fields of laboratory testing, ranging from forensic, molecular biology, medical and diagnostic applications to a wide array of basic research purposes....
4.
Van den Eede P, Van Wesenbeeck L, Verlinden Y, Feyaerts M, Smits V, Verheyen A, et al.
Methods Mol Biol
. 2013 Jul;
1030:37-55.
PMID: 23821259
Major advances in antiretroviral (ARV) therapy during the last decade have made HIV-1 infections a chronic, manageable disease. In spite of these significant advancements, ARV drug resistance remains a hurdle...
5.
Van der Borght K, Verheyen A, Feyaerts M, Van Wesenbeeck L, Verlinden Y, Van Craenenbroeck E, et al.
Virol J
. 2013 Jan;
10:8.
PMID: 23282253
Background: Integrase inhibitors (INI) form a new drug class in the treatment of HIV-1 patients. We developed a linear regression modeling approach to make a quantitative raltegravir (RAL) resistance phenotype...
6.
Pattery T, Verlinden Y, De Wolf H, Nauwelaers D, Van Baelen K, Van Houtte M, et al.
Intervirology
. 2012 Jan;
55(2):138-46.
PMID: 22286884
Objectives: A wide array of monitoring tests is commercially available to gauge HIV-1 disease progression and the overall health status of an HIV-1-infected patient. Viral load tests provide a picture...
7.
Maiga A, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, et al.
Antimicrob Agents Chemother
. 2009 Dec;
54(2):728-33.
PMID: 20008779
Susceptibility to etravirine (ETR), an expanded-spectrum nonnucleoside reverse transcriptase inhibitor (NNRTI), is dependent on the type and number of NNRTI resistance-associated mutations (RAMs). Studies have shown that some HIV-1 subtypes...
8.
Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, et al.
Antimicrob Agents Chemother
. 2009 Feb;
53(5):2185-8.
PMID: 19223634
In this study, we evaluated baseline susceptibility to bevirimat (BVM), the first in a new class of antiretroviral agents, maturation inhibitors. We evaluated susceptibility to BVM by complete gag genotypic...
9.
Verlinden Y, Cuconati A, Wimmer E, Rombaut B
J Gen Virol
. 2000 Oct;
81(Pt 11):2751-2754.
PMID: 11038388
In a cell-free system of uninfected HeLa cells, programmed with poliovirus RNA, extraneous radiolabelled 14S subunits assembled with endogenous 14S subunits and interacted with newly synthesized RNA to form virions...